A small biotech company has been compelled to begin winding down its operations after the FDA unexpectedly postponed a critical meeting by four months. This delay has significant implications for the company’s progress and highlights challenges within regulatory timelines. Meanwhile, Neurocrine Biosciences announced a new deal, signaling ongoing activity in the biotech sector despite setbacks faced by smaller players.
Back
